First Manhattan’s Neurocrine Biosciences NBIX Stock Holding History

First Manhattan’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-39	Closed	-$4.66K	–	1639
2022 Q4	$4.66K	Buy	+39	New	+$4.57K	﹤0.01%	1416
2021 Q3	–	Sell	-29	Closed	-$2K	–	1646
2021 Q2	$2K	Buy	+29	New	+$2.78K	﹤0.01%	1504
2015 Q4	–	Sell	-41,305	Closed	-$1.64M	–	1460
2015 Q3	$1.64M	Sell	41,305 -111,000	-73%	-$5.36M	0.01%	358
2015 Q2	$7.27M	Sell	152,305 -10,100	-6%	-$428K	0.04%	205
2015 Q1	$6.45M	Sell	162,405 -80,700	-33%	-$2.89M	0.04%	225
2014 Q4	$5.43M	Hold	243,105	–	–	0.03%	243
2014 Q3	$3.81M	Buy	243,105 +220,592	+980%	+$3.3M	0.02%	274
2014 Q2	$333K	Buy	+22,513	New	+$318K	﹤0.01%	593

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

First Manhattan's NBIX Position: Q1 2023 in Review

First Manhattan sold out of Neurocrine Biosciences (NBIX) in Q1 2023, closing a stake of 39 shares — an estimated $4.66K sold.

First Manhattan first reported a position in NBIX in Q2 2014 and held it in 8 quarters. The position peaked at $7.27M in Q2 2015. 486 funds tracked by Wall St. Rank hold NBIX as of Q1 2023.

First Manhattan reported no remaining Neurocrine Biosciences position as of Q1 2023 after selling out during the quarter.
First Manhattan sold 39 Neurocrine Biosciences shares in Q1 2023, an estimated $4.66K.
First Manhattan first reported a position in Neurocrine Biosciences in Q2 2014 and held it in 8 quarters.
First Manhattan's Neurocrine Biosciences position peaked at $7.27M in Q2 2015.
486 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2023.

Based on First Manhattan's 13F filing for Q1 2023, filed 15 May 2023.